Last mentioned: Mar 10, 2026
Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics reported their full-year 2025 financial results on March 10, 2026, highlighting a period of clinical execution and capital management. The updates underscore the diverging paths of commercial-stage ADC platforms and late-stage cardiovascular and neuroscience pipelines as they navigate the 2026 regulatory landscape.
This page surfaces every story mentioning TNX-201 across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where TNX-201 was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |